Development of tau aggregation inhibitors for Alzheimer's disease.
about
Novel therapeutics for Alzheimer's disease: an updatePhosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's diseaseNMR Meets Tau: Insights into Its Function and PathologyDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTDrug Development in Conformational Diseases: A Novel Family of Chemical Chaperones that Bind and Stabilise Several Polymorphic Amyloid StructuresHepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin.Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo.Isoxazolotacrines as non-toxic and selective butyrylcholinesterase inhibitors for Alzheimer's disease.Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807Why pleiotropic interventions are needed for Alzheimer's disease.Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.Human Tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability.Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cellsMacrocyclic β-sheet peptides that inhibit the aggregation of a tau-protein-derived hexapeptide.The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeuticsMolecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.Advances in tau-based drug discovery.Inhibitory effects of magnolol and honokiol on human calcitonin aggregation.Neurotrophic natural products: chemistry and biology.Rational therapeutic approaches to progressive supranuclear palsy.Challenges of longevity in developed countries: vascular prevention of dementia as an immediate clue to tackle an upcoming medical, social and economic stretch.Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.Tau as a therapeutic target for Alzheimer's diseaseAlzheimers disease: review of emerging treatment role for intravenous immunoglobulins.Potential synergy between tau aggregation inhibitors and tau chaperone modulators.Toward the discovery of effective polycyclic inhibitors of alpha-synuclein amyloid assembly.Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity.Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies.Synthetic Development of New 3-(4-Arylmethylamino)butyl-5-arylidene-rhodanines under Microwave Irradiation and Their Effects on Tumor Cell Lines and against Protein Kinases.Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.Design, Synthesis and in vitro Evaluation of Indolotacrine Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease.Crystal structure of (Z)-3-allyl-5-(4-methyl-benzyl-idene)-2-sulfanyl-idene-1,3-thia-zolidin-4-oneTau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathwaysResveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformersPolyphenolic glycosides and aglycones utilize opposing pathways to selectively remodel and inactivate toxic oligomers of amyloid β.Design, synthesis and biological evaluation of trimethine cyanine dyes as fluorescent probes for the detection of tau fibrils in Alzheimer's disease brain and olfactory epithelium.An efficient combinatorial synthesis of allocolchicine analogues via a triple cascade reaction and their evaluation as inhibitors of insulin aggregation.How curcumin affords effective protection against amyloid fibrillation in insulin.Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
P2860
Q24620383-6C10C2B1-6A05-485A-83BD-17F04CB3DAFCQ24627125-1229199B-0286-420E-8569-78A6AF85F6E8Q26747418-C56A354B-DBC3-4D67-BAE0-9DCD05D7F4C3Q26749755-218F197F-A9E4-457F-9363-7F767DFC5B7DQ28547692-8ACA6F49-0CB9-4E2F-92E1-3C6623ACBCE9Q30434199-D614A474-9F89-43BC-9FE7-F348E46A62BDQ30564297-32927D88-4969-470B-8E67-9AEB56E1979AQ30877329-36E2AFC0-B87F-451B-8942-FEEDB87D0705Q33795224-948664F5-B2AF-4197-A2AE-2879F48B2759Q33876128-04D58309-DFEE-45C3-BAFD-0F3072634458Q34064026-CBF62179-C532-4D85-9FE0-6906852D0D75Q34094582-91D4BF18-5753-4818-ABDF-37FB3DA4517AQ34103923-490E3089-08C4-42E2-8147-A5E2B65A51E5Q34624898-4A09BFB3-AEC9-40D0-BBF6-0F4011AA64E2Q35216140-432169F4-0EB8-4499-980F-33AF541CF350Q35313148-B9734E9D-50AC-418D-A52D-CB335A04BBBDQ35321539-8E06DBA9-D0F4-4EAB-B37C-1FBA3097DEF6Q36012254-08A9C256-A78F-4A28-88B1-4EE839860666Q37623342-C81159D5-97D1-465D-92B5-35E3AEDAE04FQ37753509-989BB386-0124-491B-B303-5FAC180A0B30Q37828025-8E266415-E2B9-4BF8-B173-E01FAF5C08E1Q37841631-27DB4A37-2D9E-49FF-B9F8-F89610CD3757Q37890451-3ECC6B2D-45E3-422A-A2EE-9B55F773C4C4Q38122150-67AEE04E-6267-4ABE-B3E4-CF39C486A46FQ38138165-FB87C2BB-C668-41AF-87C3-D93190694D13Q38422514-00B738F4-25AB-4A39-B1E6-2A8BED8637FAQ38592451-EFCC8FBD-5665-4761-B81F-C2CE351FE971Q38664605-1206F4F7-9DA1-491A-AEDC-12B55D592998Q38852014-4FE2A831-2E95-4B79-BA6E-B8DAEEBA17B5Q38901388-6E8E6A7F-7A7B-4D7E-A0AC-A567F33AC265Q41276257-907F10B9-3FA2-463B-AB9A-C8E34E6CFF42Q41896962-0CC812E8-3E9E-438A-BF54-1B9D38F27A83Q41945501-078EA3C0-DDA0-41E8-9E7B-D3B000F6753DQ42584937-0DB99E1E-B450-4333-BE73-6074C16E0649Q42679809-F1521BA1-8CBF-45E3-AD6B-1D933DCF1FA4Q42843362-AA63985A-D0FD-42F3-AC53-26C0975125D2Q44143296-96400F70-AA53-4749-954C-E5ADD347E161Q45135257-651B1C98-5980-42EA-AB63-46A91D5D624EQ45257868-528C9A48-6C0D-49B7-AC39-79E15CA41F0EQ46128904-929B4BE5-4228-4EA0-AB21-F1A34C600CE3
P2860
Development of tau aggregation inhibitors for Alzheimer's disease.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Development of tau aggregation inhibitors for Alzheimer's disease.
@ast
Development of tau aggregation inhibitors for Alzheimer's disease.
@en
Development of tau aggregation inhibitors for Alzheimer's disease.
@nl
type
label
Development of tau aggregation inhibitors for Alzheimer's disease.
@ast
Development of tau aggregation inhibitors for Alzheimer's disease.
@en
Development of tau aggregation inhibitors for Alzheimer's disease.
@nl
prefLabel
Development of tau aggregation inhibitors for Alzheimer's disease.
@ast
Development of tau aggregation inhibitors for Alzheimer's disease.
@en
Development of tau aggregation inhibitors for Alzheimer's disease.
@nl
P50
P356
P1476
Development of tau aggregation inhibitors for Alzheimer's disease.
@en
P2093
Bruno Bulic
Marcus Pickhardt
P304
P356
10.1002/ANIE.200802621
P407
P577
2009-01-01T00:00:00Z